macro

CagriSema Shows Strong Weight Loss in Novo Nordisk Phase 3 REDEFINE 9 Study

Novo Nordisk reported positive primary results from its Phase 3 REDEFINE 9 trial, where CagriSema cut weight by an estimated 19% to 21% over 68 weeks.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Novo Nordisk announced positive primary results from its Phase 3 REDEFINE 9 trial of CagriSema, an investigational treatment for adults with overweight or obesity. The drug combines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist, in one fixed-dose formulation. It is the first Phase 3 weight-management study to test CagriSema at doses below the 2.4 mg/2.4 mg maximum used elsewhere in the REDEFINE program.

According to TradingView, citing dpa-AFX and RTTNews, the 1.7 mg/1.7 mg group lost an estimated 20.7% of body weight over 68 weeks, the 1.0 mg/1.0 mg group lost 21.0%, and the placebo group lost 2.0%. On a treatment-regimen basis, the reductions were 19.4% and 18.6%, versus 4.6% for placebo. The share of patients losing at least 5% of body weight reached 92.8% and 87.7%, compared with 41.1% on placebo.

Both doses also produced significantly greater reductions in waist circumference, a confirmatory secondary endpoint. NVO shares rose 2.41% on Friday to close at $41.63.

why it matters

The size of the effect and the fact that it was measured at doses below the maximum both matter for investors following obesity drugs, where Novo Nordisk is a key player. Full data and the next study stages will show whether these figures become a commercial factor.

market impact

Novo Nordisk (NVO): positive trial data supports the stock and interest in obesity drugs

  • Novo Nordisk shares (NVO) pressure up — positive Phase 3 data raises expectations for the CagriSema drug

tags

instruments

NVONovo NordiskEli LillyGLP-1 drugs

sources

  1. Novo Nordisk Reports Strong Weight-Loss Results In Phase 3 REDEFINE 9 Trial Of CagriSema — TradingView, 15 November 2026 at 02:23 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗